Our 2013 Impact | Funding Allocation

Cycle for Survival works to fill the funding gap in rare cancer research—providing hope that one day, all cancer patients will have the treatment options they deserve. Since 2007, over $31.5 million has been raised for the fight.

100% of Cycle for Survival funds go directly to promising research initiatives at Memorial Sloan-Kettering Cancer Center (MSKCC) within six months of the events.

MSKCC has long been the preeminent center for research and treatment devoted exclusively to cancer. Memorial Sloan-Kettering clinicians treat over 400 types of cancer each year and the research discoveries made here benefit patients worldwide. MSKCC has produced more FDA-approved drugs for the treatment of cancer than any other single academic institution.

JOIN THE BATTLE. You can make a true difference.

Cycle for Survival 2013 was the biggest fundraising year yet! Here's how the $14,000,000 raised is being put to work:

- **$3,000,000** Pancreatic
  For essential research at the new Pancreatic Cancer Research Center.

- **$1,200,000** Pediatric
  Retinoblastoma, Neuroblastoma, Ewing’s Sarcoma, Rhabdomyosarcoma

- **$4,000,000** Molecular Oncology
  Personalized medicine impacting all rare cancers.

- **$3,000,000** Cycle for Survival Research Awards
  Head and Neck, Uveal Melanoma, Carcinosarcoma, Thyroid, Testicular, Kidney, Brain, Liver

- **$2,000,000** Jennifer Goodman Linn Laboratory of New Drug Development in Sarcoma and Rare Cancers

- **$800,000** Anaplastic Thyroid, Carcinoid, Angiosarcoma, Cholangiocarcinoma, Pancreatic Neuroendocrine, Ovarian, Lymphoma

JOIN THE BATTLE.

www.cycleforsurvival.org
Facebook.com/CycleforSurvival | @Cycle4Survival
Our 2013 Impact | Funded Research

Since 2007, Cycle for Survival funds have been allocated broadly—targeting as many areas, projects and rare cancers as possible. Our dedicated participants and donors have driven incredible growth—giving Cycle for Survival a new ability to make progress. Because of the amount raised in 2013, we are grateful for the chance to expand our funding. We will still allocate to individual, specific rare cancer research projects, but now we can advance large-scale research efforts in two areas:

- **Pancreatic Cancer Research Center**
  “Silent” in early stages, most pancreatic cancers are diagnosed far too late—overall, the five-year patient survival rate is just six percent. These stark facts highlight an urgent need—and in response, MSKCC is launching an ambitious Pancreatic Cancer Research Center. Funds from Cycle for Survival 2013 will make essential studies and clinical trials in pancreatic cancer possible—pinpointing its genetic drivers, and developing new drugs and treatments.

- **Center for Molecular Oncology**
  Dramatic advances in cancer biology prove that patients can have the same diagnosis, but different genetic mutations driving their disease. As a worldwide leader in “personalized cancer medicine,” MSKCC is launching the Center for Molecular Oncology—speeding progress toward a day when every patient receives an exactly-tailored course of treatment. Cycle for Survival 2013 funds will seed revolutionary pilot projects—allowing researchers to make discoveries that will impact rare cancer patients worldwide.

**Projects Funded Through Cycle for Survival Research Awards:**

- **Head and Neck** | Drs. José Baselga and Maurizio Scaltriti are testing a breakthrough targeted therapy against head, neck and esophageal cancers—and working to prevent or delay treatment resistance.

- **Uveal Melanoma** | Dr. Richard Carvajal is studying whether simultaneously blocking two cell signaling pathways in uveal melanoma—a rare cancer of the eye—will improve patient outcomes.

- **BCL-2 Pathway** | Dr. Emily Cheng is enhancing and testing a new drug that can kill cancer cells, and aims to apply this therapy broadly through clinical trials.

- **Carcinosarcoma** | Dr. Rachel Grisham is studying uterine and ovarian carcinosarcoma—pinpointing the mutations driving these diseases so targeted therapies can be identified, tested, and applied.

- **Thyroid** | Dr. Alan Ho is leading a Phase II clinical trial testing a drug that helps the most difficult-to-treat thyroid tumors absorb cancer-killing radioiodine.

- **Testicular** | Dr. Zsofia Stadler is using new technology to sequence DNA and identify the exact genetic causes of testicular cancer.

- **Kidney** | Dr. James Hsieh is investigating the genetic mechanisms driving a rare form of kidney cancer, and testing numerous chemotherapies for effectiveness against the disease.

- **Brain** | Dr. Andrew Koff is studying an aggressive form of brain tumor, with the goal of making radiation therapy more effective for patients.

- **Liver** | Dr. Scott Lowe is testing drugs that target two recently-discovered genetic mutations implicated in the growth of a rare form of liver cancer.

- **Thyroid** | Dr. Eric Sherman is launching a Phase I clinical trial examining a new combination drug therapy for treatment-resistant thyroid cancer.